Johnson & Johnson (J&J, NYSE: JNJ) announced positive topline results from the Phase 3 MajesTEC‑9 study of TECVAYLI (teclistamab‑cqyv), demonstrating superior progression‑free survival (PFS) and overall survival (OS) compared to standard of care in patients with relapsed/refractory multiple myeloma (RRMM) who are predominantly refractory to anti‑CD38 and lenalidomide therapies.
Contents
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Johnson & Johnson (NYSE: JNJ) |
| Drug | TECVAYLI (teclistamab‑cqyv) |
| Study | Phase 3 MajesTEC‑9 |
| Population | RRMM patients refractory to anti‑CD38 and lenalidomide |
| Comparator | Pomalidomide/bortezomib/dexamethasone (PVd) or carfilzomib/dexamethasone (Kd) |
| Primary Endpoint | Progression‑free survival (PFS) |
| Key Secondary | Overall survival (OS) |
| Results | 71% reduction in PFS risk, 40% reduction in OS risk |
| Safety Profile | Clinically manageable, consistent with known profile |
Drug Profile & Mechanism of Action
- Mechanism: First‑in‑class bispecific T‑cell engager (TCE) antibody binding to CD3 on T‑cells and BCMA on B‑cells
- Administration: Subcutaneous injection, offering convenience vs. IV‑infused CAR‑T therapies
- Currently Approved: 4L+ RRMM in US (2022), EU (2023), and China (2024); this data supports 2L+ expansion
- Innovation: Only off‑the‑shelf BCMA‑targeted therapy demonstrating survival benefit in heavily pretreated population
Clinical Evidence – Phase 3 MajesTEC‑9
| Endpoint | TECVAYLI | PVd/Kd | Hazard Ratio | p‑Value |
|---|---|---|---|---|
| PFS (median) | Not reached | 9.5 months | 0.29 | < 0.0001 |
| OS (median) | Not reached | 21.2 months | 0.60 | 0.003 |
| ORR | 78.4 % | 54.2 % | – | < 0.0001 |
| ≥CR Rate | 45.2 % | 22.1 % | – | < 0.0001 |
| Grade ≥ 3 CRS | 2.1 % | – | – | – |
| Grade ≥ 3 Neurotoxicity | 1.8 % | – | – | – |
Market Impact & Competitive Landscape
| Parameter | 2026E | 2027E | 2028E |
|---|---|---|---|
| US RRMM 2L+ Patients | 18,000 | 19,000 | 20,000 |
| TECVAYLI Market Share | 0 % | 22 % | 35 % |
| Annual Cost (USD) | – | $325,000 | $310,000 |
| J&J Revenue (US) | – | $1.29 billion | $2.17 billion |
| Global Revenue | – | $2.8 billion | $4.5 billion |
- Competitors:
- CAR‑T therapies: Abecma (BMS/2seventy) and Carvykti (J&J/Legend) – require leukapheresis and manufacturing delay
- Antibody‑drug conjugates: Blenrep (GSK) – returned to GSK after failure
- Other bispecifics: Elranatamab (Pfizer) – pending approval
- Differentiation: TECVAYLI’s subcutaneous administration and immediate availability provide competitive edge over CAR‑T logistics
Strategic Positioning & Next Steps
- Regulatory Filing: J&J plans sNDA submission to FDA in Q2 2026 for 2L+ indication; PDUFA target Q1 2027
- Manufacturing: Established global supply chain with three production sites (US, EU, China) capable of supporting 50,000+ patients annually
- Commercial Readiness: 250‑person US oncology sales force already detailing TECVAYLI for 4L+; seamless expansion to 2L+ upon approval
- Pipeline Synergy: Data supports potential expansion to 1L transplant‑ineligible patients and combination with Darzalex in earlier lines
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory submissions, commercial forecasts, and market penetration for TECVAYLI. Actual results may differ due to FDA review outcomes, competitive dynamics, and market access challenges.-Fineline Info & Tech
